Transferrin saturation with intravenous irons: an in vitro study

Area of Science:

• Pharmacology
• Nephrology
• Biochemistry

Background:

• Intravenous iron formulations (iron dextran, iron sucrose, iron gluconate) are standard treatments for iron deficiency anemia in chronic kidney disease.
• Pharmacologic differences exist among these agents, but their comparative ability to saturate transferrin remains uncharacterized.
• Rapid transferrin saturation may influence both therapeutic efficacy and potential toxicity.

Purpose of the Study:

• To compare the in vitro ability of three intravenous iron formulations to donate iron to transferrin.
• To assess dose- and time-dependent transferrin saturation kinetics for iron dextran, iron sucrose, and iron gluconate.

Main Methods:

• In vitro study evaluating iron donation to transferrin.
• Urea polyacrylamide gel electrophoresis (PAGE) for direct visualization of transferrin bands.
• Functional assay to determine the half-maximal effective concentration (EC50) for transferrin saturation.
• Dose- (0-100 microg/mL) and time- (15-180 min) dependent analyses were performed.

Main Results:

• Iron sucrose and iron gluconate demonstrated dose- and time-dependent transferrin saturation, unlike iron dextran.
• Iron gluconate achieved more rapid transferrin saturation than iron sucrose.
• Calculated EC50 values indicated greater iron transfer efficiency: iron gluconate (5.95 nmol) > iron sucrose (6.73 nmol) > iron dextran (7.24 nmol).

Conclusions:

• Significant in vitro heterogeneity exists in the direct iron transfer capabilities of parenteral iron formulations.
• These observed differences suggest potential variations in in vivo safety and efficacy among these intravenous iron agents.
• Further in vivo studies are warranted to elucidate the therapeutic ratio of nondextran parenteral irons.